Malaria is still a serious global health threat, with 249 million cases and 608,000 deaths recorded in 2022. Plasmodium resistance to chloroquine is a major challenge that drives the need for new therapeutic strategies based on drug combinations. This study aims to test the antimalarial activity of the combination of chloroquine and ursolic acid against Plasmodium berghei ANKA in male Swiss Webster mice in vivo using the 4-day suppressive Peters method. The test animals were divided into six groups: negative control (Na CMC 0.5%), chloroquine 20 mg/kg BB, ursolic acid 50 mg/kg BB, as well as three combination groups with different dose ratios. The parameters observed included percent of parasitemia, percent growth, and percent of parasite resistance. The results showed that the combination of chloroquine 15 mg/kg BB and ursolic acid 12.5 mg/kg BB resulted in 100% parasite growth inhibition, equivalent to chloroquine monotherapy at 20 mg/kg BB. Other combinations also showed very high resistance (96.15–98.49%). These findings indicate that ursolic acid has the potential to be a complementary agent that allows for a reduction in chloroquine dose without reducing the effectiveness of therapy.
Copyrights © 2026